These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31704739)

  • 1. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.
    Kadatz M; Gill JS; Gill J; Formica RN; Klarenbach S
    J Am Soc Nephrol; 2020 Jan; 31(1):218-228. PubMed ID: 31704739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant.
    Yen EF; Hardinger K; Brennan DC; Woodward RS; Desai NM; Crippin JS; Gage BF; Schnitzler MA
    Am J Transplant; 2004 Oct; 4(10):1703-8. PubMed ID: 15367228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients.
    Page TF; Woodward RS
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):435-44. PubMed ID: 19817527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of lifetime immunosuppression coverage for kidney transplant recipients.
    Page TF; Woodward RS
    Health Care Financ Rev; 2008; 30(2):95-104. PubMed ID: 19361119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
    Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
    Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
    Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.
    Tanriover B; Stone PW; Mohan S; Cohen DJ; Gaston RS
    Clin J Am Soc Nephrol; 2013 Jul; 8(7):1258-66. PubMed ID: 23559679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The financial impact of immunosuppressant expenses on new kidney transplant recipients.
    Gordon EJ; Prohaska TR; Sehgal AR
    Clin Transplant; 2008; 22(6):738-48. PubMed ID: 18673373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage.
    Woodward RS; Page TF; Soares R; Schnitzler MA; Lentine KL; Brennan DC
    Am J Transplant; 2008 Dec; 8(12):2636-46. PubMed ID: 19032227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending Medicare immunosuppressive medication coverage.
    Beaubrun AC
    J Health Care Poor Underserved; 2012 Feb; 23(1):20-7. PubMed ID: 22643460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-related immunosuppressive medication nonadherence among kidney transplant recipients.
    Evans RW; Applegate WH; Briscoe DM; Cohen DJ; Rorick CC; Murphy BT; Madsen JC
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2323-8. PubMed ID: 20847093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare Part D coverage and its influence on transplant patients' out-of-pocket prescription expenses.
    Chisholm MA; Roberts E
    Am J Transplant; 2006 Jul; 6(7):1737-42. PubMed ID: 16827879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis.
    Ying T; Tran A; Webster AC; Klarenbach SW; Gill J; Chadban S; Morton R
    Am J Kidney Dis; 2020 May; 75(5):693-704. PubMed ID: 31810731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare immunosuppressant coverage and access to kidney transplantation: a retrospective national cohort study.
    Grubbs V; Plantinga LC; Vittinghoff E; O'Hare AM; Dudley RA
    BMC Health Serv Res; 2012 Aug; 12():254. PubMed ID: 22894737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of basiliximab in renal transplantation.
    Keown PA; Balshaw R; Krueger H; Baladi JF
    Transplantation; 2001 Jun; 71(11):1573-9. PubMed ID: 11435967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
    Chisholm MA; Marshall J; Smith KE; Garrett CJ; Turner JC
    Clin Transplant; 2005 Jun; 19(3):357-63. PubMed ID: 15877798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2016 Oct; 19(10):995-1002. PubMed ID: 27172118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.